GEGonca Erbaş

Gonca Erbaş

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gonca Erbaş has a total of 130 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Bronchiolitis Obliterans Syndrome After Allogeneic HSCT: Clinical Characteristics and Survival Outcomes in a Single Center Cohort

    by Emine Merve Savaş, Nurdan Kokturk, Ahmet Alparslan Ceran, Şeyma Yıldız, Münevver İrem Kök Yılmaz, Başak Bostankolu Değirmenci, Zeynep Arzu Yeğin, Gonca Erbaş, Özlem Güzel Tunçcan, Aysun Sarıer, et al.

    Background/Objectives: Chronic graft-versus-host disease (cGVHD) remains a significant complication after allogeneic stem cell transplantation. Bronchiolitis obliterans syndrome (BOS), the best characterized form of pulmonary cGVHD, represents its most severe and therapeutically challenging manifestation and is associated with poor long-term outcomes. However, data on treatment responses and survival remain limited. Methods: We performed a retrospective, single-center study to characterize the clinical features, treatment responses, and survival outcomes of patients with BOS following allo-HSCT. Results: Between January 2003 and December 2023, 28 (4.1%) of 678 transplanted patients met the National Institutes of Health (NIH) diagnostic criteria for BOS with lung scores of 2–3. The median age was 26 years (21–51), and 67.9% were male. The median time from transplantation to BOS diagnosis was 20.9 months (11.2–45.9). Median forced expiratory volume in one second (FEV1) declined from 97.5% at transplantation to 47.5% at BOS diagnosis, while median diffusing capacity for carbon monoxide (DLCO) decreased from 72% to 35% of predicted.The best observed response was partial response (PR). The overall first-line steroid-based response rate was 14.3%. In second- and subsequent-line settings, PR rates were 25% with ibrutinib, 25% with extracorporeal photopheresis, 33.3% with ruxolitinib, and 20% with mesenchymal stem cell therapy, while no responses were observed with imatinib. Median overall survival from transplantation was 90.9 months (48.4–133.5), whereas median survival from BOS diagnosis was 27.2 months (17.4–156.9). Survival after BOS diagnosis was significantly longer in patients with a prior history of acute GVHD (79.7 vs. 25.7 months; p = 0.026) and in those with concomitant extrapulmonary cGVHD compared with isolated BOS (79.7 vs. 7.6 months; p = 0.001). Conclusions: Treatment responses in stage 2–3 BOS were limited, and survival remained very poor, highlighting the importance of earlier recognition and more effective therapies before fibrotic progression.

  • Open Access

    Correction to: Clinical, laboratory and molecular features of glycogen storage disease type 1a and 1b patients from Turkey: novel mutations and phenotypes

    by Ayşe Akyüz, İlYas Okur, Leyla Tümer, Fatma Tuba Eminoğlu, Engin Köse, Filiz Başak Ergin, Aslı İnci, Buket Dalgıç, Burcu Yüce, Bahattin Çiftçi, et al.

  • Open Access

    COVID-19 Vaccine Response in Allo-HSCT Recipients: Insights from a Real-World Prospective Cohort Study

    by Emine Merve Savaş, Şeyma Yıldız, Zübeyde Nur Özkurt, Zehra Baltacı, Özlem Güzel Tunçcan, Zeynep Arzu Yeğin, Kayhan Çağlar, Nurdan Köktürk, Gonca Erbaş, Gülendam Bozdayı, et al.

    Background: Allogeneic hematopoietic stem cell transplant (Allo-HSCT) recipients are still at increased risk of severe COVID-19 infection. Vaccination is a critical strategy to protect this population. This real-world prospective cohort study aimed to evaluate the immune response and clinical outcomes of COVID-19 vaccines in Allo-HSCT recipients. Methods: Allo-HSCT recipients (median age: 48 years) who received either the BNT162b2 or CoronaVac vaccines were included. Antibodies against the SARS-CoV-2 spike protein were quantitatively measured using the chemiluminescent microparticle immunoassay. Patient- and vaccine-related factors affecting antibody responses were analyzed. Adverse events, including graft-versus-host disease (GVHD) and post-vaccine infections, were recorded. Results: Among 95 Allo-HSCT recipients, 86.3% achieved adequate antibody responses following COVID-19 vaccination. Patients receiving ≥3 vaccine doses showed significantly higher antibody titers compared to those with only 2 doses (OR: 0.11; 95% CI: 0.02–0.53; p = 0.006 **). The use of Ruxolitinib or Ibrutinib was associate with increased odds of low antibody response (OR: 38.39; 95% CI: 3.14–468.95; p = 0.004 **). Hypogammaglobulinemia (low serum IgG levels) was associated with a reduced antibody response (OR: 0.17; 95% CI: 0.03–0.96; p = 0.045 *), while no significant correlation was found between serum IgA levels and antibody responses (p = 0.672). Three cases of post-vaccine GVHD were observed, and no fatalities related to COVID-19 occurred during the study. Conclusions: COVID-19 vaccination is safe and effective in Allo-HSCT recipients, with stronger responses especially following ≥3 vaccine doses. Patients receiving GVHD treatment or with hypogammaglobulinemia exhibited impaired responses, emphasizing the need for tailored vaccination strategies and close monitoring in this population.


  • Correlation between Platelet-to-Lymphocyte Ratio, Neutrophil-to-Lymphocyte Ratio and Burden of Thrombus with Disease Severity in Patients with Pulmonary Thromboembolism

    by Ayshan Mammadova, Kübra Taşkaraca, Günel Jeyranova, Aysel Orujlu, Merve Tatlılıoğlu, Serra Duygulu, Zeynep Yalçınkaya, Seriyye Allahverdiyeva, Onur Gündoğdu, Atiye Cenay Karabörk Kılıç, et al.

    High neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are markers of subclinical inflammation and have been associated with prognosis and mortality in many diseases. In this study, we evaluated the comparative value of NLR and PLR in identifying high mortality risk in patients hospitalized with acute pulmonary thromboembolism (PTE), and their relationship with the anatomical burden of thrombus.Patients who were followed up due to PTE were evaluated retrospectively. NLR and PLR were calculated from complete blood counts. The thrombus burden was assessed by the Qanadli score; based on the patients' archival computed tomography angiography images. Mortality prediction was based on an algorithm using the Pulmonary Embolism Severity Index, echocardiographic findings, and troponin levels.Three hundred-two PTE patients were included in the study. Median NLR, PLR, and Qanadli score values were higher in nonsurvivors, with NLR (8.4 [2.2–18.9]) vs. (3.1 [0.4–13.1]), PLR (317 [87.6–525.3]) vs. (124.4 [30–476.3]), and Qanadli scores (21 [3–26]) vs. (9 [1–28]), respectively (p < 0.001). We showed that setting a threshold value of >4.45 for NLR and >151.59 for PLR significantly predicts the high mortality-risk group. In the receiver operating characteristic analysis, when the threshold value for the Qanadli score distinguishing between low-risk and high-risk disease was set at 15.5, the sensitivity was calculated as 98.8% and the specificity was 94.9% (p = 0.001).This study showed that NLR, PLR, and Qanadli scores can provide essential contributions to the clinician's determination of the anatomical burden of thrombus and disease severity in PTE patients.


  • Eosinophilic Lung Diseases

    by Gonca Erbaş

  • Open Access

    Third generation dual-source CT coronary angiography with high-pitch spiral mode versus prospectively-gated sequential mode: comparison of radiation exposure and image quality

    by Aydan Avdan Aslan, Gonca Erbaş, Leyla Salımlı, Koray Kılıç, Mehmet Araç

    Objectives: To compare high-pitch spiral (HPS) and prospectively-gated step-and-shoot (SAS) coronary CT angiography (CCTA) using third generation dual-source CT regarding objective and subjective image quality parameters and radiation exposure. Methods: Eighty pairs of patients matched for gender, age, heart rate and BMI were enrolled in this retrospective study. High-pitch spiral and prospectively ECG-gated sequential CCTA were performed using third generation dual-source CT. The signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) in the left ventricle were calculated for each group. Image quality were also scored using four-point scale. Student t-test was used to compare SNR, CNR and mean effective dose values (ED) and Wilcoxon test was used to compare image quality scores. Interrater aggreement were evaluated using Cohen’s kappa statistics. Results: Between-group differences in terms of age, gender, BMI, heart rate, and Agatston score were statistically not significant. Mean SNR and CNR was higher in prospective SAS protocol (16.5 ± 6.2 vs. 14.7 ± 4.9, p = 0.047 and 13.0 ± 5.2 vs. 11.2 ± 4.3, p = 0.02). Image quality scores showed no significant difference between two scan protocols (p > 0.05). Regarding radiation exposure, CT dose index (CTDIvol), dose length product (DLP) and ED was significantly lower for high-pitch group (p < 0.0001). Conclusions: HPS CCTA using DSCT enables > 70% dose reduction while maintaining the image quality compared to prospectively ECG-gated SAS protocol. Therefore, HPS CCTA protocol can be preferred in patients appropriate for prospective ECG-triggered protocol.

  • COVID-19 Enfeksiyonunun Hematolojik Maligniteli Hastalar Üzerine Etkiler

    by Lale Aydın Kaynar, Özlem Güzel Tunçcan, Asena Dikyar, Başak Bostankolu, Gülendam Bozdayı, Gonca Erbaş, Nurdan Köktürk, Zeynep Arzu Yeğin, Zübeyde Nur Özkurt, Münci Yağcı

  • Open Access

    Gamma-glutamyl transferase to albumin ratio can predict severity of coronary artery disease detected by coronary computed tomography angiography

    by Salih Topal, Emrullah Kızıltunç, Burak Sezenöz, Mustafa Candemir, Serkan Ünlü, Muhammet Küçükbardaslı, Ayşe Nihan Bal, Hüseyin Koray Kılıç, Gonca Erbaş, Adnan Abacı

    Gamma-glutamyl transferase (GGT) to albumin ratio (GAR) has been shown to be helpful to diagnose and determine the severity of coronary artery disease (CAD). Coronary computed tomography angiography (CCTA) is a guide recommended non-invasive test that provides information about the presence, severity, and morphology of coronary plaques. In this study, our main aim was to investigate the relationship between the presence, morphology, and severity of coronary plaques detected via CCTA and GAR in patients with low to moderate risk for undiagnosed CAD. Nine hundred and sixty six patients were included who underwent CCTA. The severity of CAD and plaque morphology were investigated. CT-adapted Leaman score (CT-LeSc) was calculated to determine the extent of the CAD. The study population was further evaluated in three groups according to tertiles of GAR. Atherosclerotic plaques were more common in the male gender and older patients with conventional cardiovascular risk factors. GAR was significantly lower in patients with normal CCTA than in patients with a non-obstructive plaque or obstructive plaque on CCTA. Patients in upper GAR tertiles had a higher coronary calcium score (CACS) and CT-LeSc. GAR was one of the independent predictors to predict severe stenotic plaque and high CACS. GAR can independently predict the presence, extent, and severity of CAD determined by CT-LeSc. We believe as a cheap, safe, and widely available tool, GAR would be useful in the diagnosis of CAD.


  • Relationship between chest computed tomography findings and clinical conditions of coronavirus disease (COVID‐19): A multicentre experience

    by Nilgün Yılmaz Demirci, Asiye Uğraş Dikmen, Cantürk Taşçı, Deniz Doğan, Yakup Arslan, Nesrin Öcal, Mustafa Taşar, Uğur Bozlar, Cumhur Artuk, Gülden Yılmaz, et al.

    Aims This study aimed to investigate the clinical and chest computed tomography (CT) features associated with clinical parameters for coronavirus disease (COVID-19) in the capital of Turkey, Ankara. Materials and methods Epidemiological, clinical features, laboratory findings and radiological characteristics of 1563 hospitalised patients with COVID-19 in Ankara were collected, reviewed and analysed in this study. The risk factors associated with disease severity were investigated. Results Non-severe (1214; 77.7%) and severe cases (349; 22.3%) were enrolled in the study. Compared with the non-severe group, the severe group were significantly older and had more comorbidities (ie, hypertension, diabetes mellitus, cardiovascular disease and chronic kidney disease). Smoking was more common in the severe group. Severe patients had higher respiratory rates and higher incidences of cough and dyspnoea compared with non-severe patients. Compared with the non-severe patients, the severe patients had increased C-reactive protein (CRP), procalcitonin, neutrophil to lymphocyte ratio (NLR) and CRP/albumin ratio and decreased albumin. The occurrence rates of consolidation, subpleural sparing, crazy-paving pattern, cavity, halo sign, reversed halo sign, air bronchogram, pleural thickening, micronodule, subpleural curvilinear line and multilobar and bilateral involvement in the CT finding of the severe patients were significantly higher than those of the non-severe patients. Conclusions Many factors are related to the severity of COVID-19, which can help clinicians judge the severity of the patient and evaluate the prognosis. This cohort study revealed that male sex, age (≥55 years), patients with any comorbidities, especially those with cardiovascular disease, dyspnoea, increased CRP, D-dimer and NLR, and decreased lymphocyte count and CT findings of consolidation and multilobar involvement were predictors of severe COVID-19.